Study may explain why some triple-negative breast cancers are resistant to chemotherapy

April 19, 2018, University of Texas M. D. Anderson Cancer Center
Credit: CC0 Public Domain

Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many patients become resistant to treatment. A team at The University of Texas MD Anderson led a study which may explain how resistance evolves over time, and potentially which patients could benefit from chemotherapy.

Results from a study led by Nicholas Navin, Ph.D., associate professor of Genetics, were published today in the April 19, 2018 online issue of Cell. Their findings indicate breast cancer cell to chemotherapy may be pre-existing and the may even adapt to become resistant when confronted by the chemotherapy itself.

To answer how a cell becomes resistant to chemotherapy, one must understand that cancer often begins with a clone - a single mutated cell that either can be destroyed by the immune system, or mutated further as subclones, genetic aberrations resulting in an ever-evolving cellular pathway to cancer.

"An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or, alternatively, through the acquisition of new genomic aberrations," said Navin. "Our data showed that resistant genotypes, or genes prone to being cancer-resistant, were pre-existing and adaptively selected by the initial treatment known as neo-adjuvant chemotherapy, but also requires further changes in gene expression programs to become fully resistant."

Neo-adjuvant chemotherapy (NAC) is the standard of care for many TNBC patients, who lack estrogen and progesterone receptors as well as human epidermal growth factor 2 (HER2) receptor, making them ineligible for hormone or anti-HER2 therapy. While NAC is effective in some TNBC patients, approximately half will develop , leading to poor overall survival.

"A major gap in knowledge is whether chemoresistance arises due to the selection and expansion of pre-existing subclones called adaptive resistance or through new mutations resulting from the chemotherapy, a phenomenon known as acquired resistance," said Navin. "Previous genomic studies in other cancers have shown either adaptive or acquired resistance in different types."

Navin's group studied 20 TNBC patients treated with NAC. They looked at genetic changes by deeply sequencing the coding regions of genes across the genome. They sought to understand whether new genetic mutations occurring after chemotherapy erupted spontaneously due to acquired resistance, or whether the mutations already existed at very low levels prior to treatment.

"What we found were two distinct classes of clonal dynamics - extinction and persistence," said Navin. "In the clonal extinction patients, NAC eliminated the tumor cells, leaving only normal cell types post-treatment. Clonal persistent patients harbored a larger number of residual tumor cells with genotypes and phenotypes that were altered in response to NAC."

Using single-cell DNA and RNA sequencing, his team performed a detailed analysis of eight clonal persistent patients, measuring miniscule portions of DNA and RNA and found responses to NAC were pre-existing, thus adaptively selected. However, the expression of resistant genes was acquired by subsequent reprogramming as a result of .

"Our data support a model of chemoresistance in which two modes of evolution, adaptive and acquired, were operating to establish chemo-resistant tumor mass," said Navin. "This data has important clinical implications."

Navin's group believes pre-existence of chemoresistant genotypes in tumors indicates there may be diagnostic opportunities for detecting chemoresistant clones in TNBC patients prior to receiving NAC. Their findings that TNBC patients fall into clonal extinction or clonal persistent groups may be applicable to patient outcomes or survival.

"Lastly, our data raise the possibility of therapeutic strategies to overcome chemoresistance by targeting pathways identified in this study," said Navin. "Future work will need to be performed in a larger group of TNBC to fully understand this evolutionary model and gene-related chemoresistance."

Explore further: New liquid biopsy-based cancer model reveals data on deadly lung cancer

Related Stories

New liquid biopsy-based cancer model reveals data on deadly lung cancer

April 15, 2018
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University ...

Same cancer, different time zone

July 30, 2014
Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.

Identification of a chemotherapy resistance factor in breast cancer patients

May 19, 2016
Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 ...

'Bursts' of chromosome changes fuel breast cancer tumor growth

August 15, 2016
As with most cancers, triple-negative breast cancer (TNBC) cells have abnormal amounts of chromosomes or DNA copy number aberrations (CNAs) in their genomes. A new study used single cell sequencing technology to provide previously ...

Getting a GRiP on chemoresistance: A review of GRP78 as a therapeutic target in cancer

March 1, 2018
Innate or acquired resistance to current standard-of-care therapies is a major hindrance to successful chemotherapeutic intervention. There is a critical need to elucidate the underlying mechanisms responsible for chemoresistance ...

Study finds explanation for some treatment-resistant breast cancers

April 21, 2016
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are ...

Recommended for you

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.